Flow cytometry beads rather than the antihuman globulin method should be used to detect HLA Class I IgG antibody (PRA) in cadaveric renal regraft candidates

被引：7

作者：

Bryan, CF ^{[1
]}

McDonald, SB ^{[1
]}

Baier, KA ^{[1
]}

Luger, AM ^{[1
]}

Aeder, MI ^{[1
]}

Murillo, D ^{[1
]}

Muruve, NA ^{[1
]}

Nelson, PW ^{[1
]}

Shield, CF ^{[1
]}

Warady, BA ^{[1
]}

机构：

[1] Midwest Transplant Network, Westwood, KS 66205 USA

来源：

CLINICAL TRANSPLANTATION | 2002年 / 16卷

关键词：

Class IPRA; flow PRA; regrafts; renal;

D O I：

10.1034/j.1399-0012.16.s7.2.x

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

HLA Class I antibody screening can be performed by flow cytometry using a mixture of 30 distinct bead populations each coated with the Class I antigen phenotype derived from different cell lines. In this study we compared the efficacy of Class I antibody screens done by flow cytometry beads with the antihuman globulin (AHG) method for patients awaiting cadaveric renal retransplantation. Class I panel reactive antibody (PRA) screening by flow cytometric beads of 21 regraft serum samples that had all been found to be negative by AHG DTT Class I PRA, revealed that 57.1% (12 of 21) had a flow Class I PRA of greater than or equal to 10%. Furthermore, when five regraft sera with an intermediate PRA were screened (mean AHG DTT PRA = 33.2 +/- 13%) the mean flow Class I PRA almost doubled (mean flow PRA = 72.4 +/- 10.2%) ( p < 0.01). When active UNOS waiting list regraft candidates, after several months of screening the Class I PRA by flow beads, were divided into the three PRA categories based on their peak flow Class I PRA value (0-20%, 21-79% and ≥ 80%), the incidence of a positive flow cross-match was 0%, 72% and 85% and the incidence of retransplantation was 60%, 22% and 10%, in each of these groups, respectively. These data provided our histocompatibility laboratory with the rationale to stop performing the AHG PRA and perform only the flow Class I PRA method for regraft candidates.

引用

页码：15 / 23

页数：9

共 15 条

[11] Simultaneous HLA class I and class II antibodies screening with flow cytometry [J].